BEAM Therapeutics, a biotechnology company focused on developing precision genetic medicines through base editing, stands at a critical juncture in its clinical development journey. The company’s ...
Analysts have set 12-month price targets for Beam Therapeutics, revealing an average target of $44.5, a high estimate of $74.00, and a low estimate of $28.00. This current average reflects an increase ...
Below is Validea's guru fundamental report for BEAM THERAPEUTICS INC (BEAM). Of the 22 guru strategies we follow, BEAM rates highest using our Value Investor model based on the published strategy of ...
Below is Validea's guru fundamental report for BEAM THERAPEUTICS INC (BEAM). Of the 22 guru strategies we follow, BEAM rates highest using our Value Investor model based on the published strategy of ...
Researchers have developed a muon-based approach to non-destructive investigations for unique asteroid samples, report scientists. Japanese researchers from Osaka University have developed a ...
The Timoshenko beam theory extends the classical Euler–Bernoulli approach by incorporating transverse shear deformation and rotational inertia. This advancement allows for a more accurate ...
I’ve been following trinamiX ever since I first met with the company back in 2018 at Mobile World Congress Barcelona. Back then, it was a somewhat newly formed subsidiary of BASF, spun-off in 2015.
Beam Global, North American maker of solar-based infrastructure for use in various clean energy and electric transportation projects, is likely not on many investors’ radar. With a market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results